Ibrutinib monotherapy in relapsed or refractory, transformed diffuse large B-cell lymphoma

BACKGROUND: Histological transformation to diffuse large B-cell lymphoma (tDLBCL) occurs in a significant proportion of indolent lymphomas. However, few studies of novel agents inform its management, particularly when relapsed after or refractory (R/R) to prior treatment. PATIENTS AND METHODS: We pr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Lymphoma Myeloma Leuk
Hauptverfasser: Graf, Solomon A., Cassaday, Ryan D., Morris, Karolyn, Voutsinas, Jenna M., Wu, Qian Vicky, Behnia, Sanaz, Lynch, Ryan C., Krakow, Elizabeth, Rasmussen, Heather, Chauncey, Thomas R., Kanan, Sandra, Soma, Lorinda, Smith, Stephen D., Gopal, Ajay K.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2020
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7904587/
https://ncbi.nlm.nih.gov/pubmed/33358575
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2020.11.023
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge